Neuralstem (NASDAQ:CUR) vs. Eiger Biopharmaceuticals (NASDAQ:EIGR) Head to Head Comparison

Share on StockTwits

Neuralstem (NASDAQ:CUR) and Eiger Biopharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Neuralstem and Eiger Biopharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuralstem 0 0 0 0 N/A
Eiger Biopharmaceuticals 0 0 7 0 3.00

Eiger Biopharmaceuticals has a consensus price target of $30.82, indicating a potential upside of 214.46%. Given Eiger Biopharmaceuticals’ higher possible upside, analysts clearly believe Eiger Biopharmaceuticals is more favorable than Neuralstem.

Risk and Volatility

Neuralstem has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Eiger Biopharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares Neuralstem and Eiger Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuralstem -39,417.64% -170.51% -110.16%
Eiger Biopharmaceuticals N/A -114.30% -69.08%

Institutional and Insider Ownership

5.2% of Neuralstem shares are owned by institutional investors. Comparatively, 71.2% of Eiger Biopharmaceuticals shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Comparatively, 5.8% of Eiger Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Neuralstem and Eiger Biopharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuralstem $260,000.00 13.57 -$4.93 million N/A N/A
Eiger Biopharmaceuticals N/A N/A -$52.39 million ($3.82) -2.57

Neuralstem has higher revenue and earnings than Eiger Biopharmaceuticals.

Summary

Eiger Biopharmaceuticals beats Neuralstem on 7 of the 10 factors compared between the two stocks.

Neuralstem Company Profile

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.